Brilliant Violet 750™ anti-mouse CD45.2 Antibody, CD45.2, 104,BioLegend,109857

The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4,in vivoandin vitroblocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3.

Host

Mouse

Reactivity

Mouse

Application

FC -Quality tested

Platform ID

BAB036871702

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameBrilliant Violet 750™ anti-mouse CD45.2 Antibody, CD45.2, 104
Cat. No.109857
HostMouse
RRIDAB_2832376 (BioLegend Cat. No. 109857)
IsotypeMouse (SJL) IgG2a, κ
ReactivityMouse
ApplicationFC -Quality tested
ClonalityMonoclonal
Clone Number104
Concentration0.2 mg/mL
TargetCD45.2
ImmunogenB10.S mouse thymocytes and splenocytes
PurityThe antibody was purified by affinity chromatography and conjugated with Brilliant Violet 750™ under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Regulatory StatusResearch Use Only

Scientific Background

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.